McKesson (MCK) – Research Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of McKesson (NYSE: MCK) in the last few weeks:

• 12/22/2025 – McKesson had its “buy (a-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – McKesson had its “buy” rating reaffirmed by analysts at Cowen Inc.
• 12/15/2025 – McKesson had its “buy (a-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/10/2025 – McKesson had its “buy” rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft.
• 12/8/2025 – McKesson is now covered by analysts at Barclays PLC. They set an “overweight” rating and a $960.00 price target on the stock.
• 12/8/2025 – McKesson had its “buy (a-)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – McKesson was upgraded by analysts at Barclays PLC to a “strong-buy” rating.
• 12/1/2025 – McKesson had its “buy (a-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – McKesson had its “buy (a-)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – McKesson was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating.
• 11/19/2025 – McKesson was upgraded by analysts at Weiss Ratings from a “buy (b+)” rating to a “buy (a-)” rating.
• 11/13/2025 – McKesson had its “buy (b+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/10/2025 – McKesson had its price target raised by analysts at Wells Fargo & Company from $816.00 to $914.00. They now have an “equal weight” rating on the stock.
• 11/8/2025 – McKesson was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 11/6/2025 – McKesson had its “outperform” rating reaffirmed by analysts at Evercore ISI. They now have a $1,000.00 price target on the stock.
• 11/6/2025 – McKesson had its price target raised by analysts at Robert W. Baird from $873.00 to $927.00. They now have an “outperform” rating on the stock.
• 11/6/2025 – McKesson had its price target raised by analysts at UBS Group AG from $920.00 to $980.00. They now have a “buy” rating on the stock.
• 11/6/2025 – McKesson had its price target raised by analysts at Morgan Stanley from $857.00 to $916.00. They now have an “overweight” rating on the stock.
• 10/27/2025 – McKesson had its price target raised by analysts at UBS Group AG from $860.00 to $920.00. They now have a “buy” rating on the stock.
• 10/27/2025 – McKesson was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.

McKesson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 2nd. Shareholders of record on Monday, December 1st will be given a $0.82 dividend. This represents a $3.28 annualized dividend and a yield of 0.4%. The ex-dividend date is Monday, December 1st. McKesson’s dividend payout ratio is currently 10.21%.

Insider Activity at McKesson

In other news, CAO Napoleon B. Rutledge, Jr. sold 329 shares of McKesson stock in a transaction that occurred on Friday, November 7th. The shares were sold at an average price of $861.63, for a total transaction of $283,476.27. Following the completion of the transaction, the chief accounting officer directly owned 328 shares of the company’s stock, valued at $282,614.64. The trade was a 50.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.08% of the stock is owned by insiders.

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.